TVS Motor Company launches its revolutionary premium electric crossover, TVS X; sets new global benchmarks in the EV industry
In line with its commitment towards offering sustainable mobility solutions globally, TVS Motor Company, a reputed manufacturer of two and three-wheelers, today launched the keenly anticipated, TVS X its flagship crossover EV with a host of industry first attributes. This revolutionary machine sets a new benchmark in the global electric mobility industry with its stunning design, unmatched performance, and cutting-edge tech features, carving out a new category in the electric mobility segment. As a frontrunner in sustainable mobility solutions, TVS Motor Company aims to transform the EV segment and reaffirm its commitment to a more sustainable and cleaner future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230824401679/en/
Mr. Sudarshan Venu, MD, TVS Motor Company at the launch of TVS X in Dubai (Photo: Business Wire)
With a rapid uptick in the adoption of EVs globally, the TVS X will play a pivotal role in creating a niche in the EV industry. Backed by rider-first engineering, to deliver rider-machine unity, this lean-mean-clean machine designed to create desire, has been developed from the ground up at TVS Motor’s R&D facility. Designed, developed, and made-in-India, TVS X comes with a powerful electric motor and advanced battery technology. This machine promises not only thrilling acceleration but also an impressive range, ensuring convenience and comfort, thus making it an ideal zero-emission and sophisticated electric mobility solution. This flagship EV from the house of TVS Motor introduces not only stellar performance, but also an array of safety features, with a number of class leading offerings in line with its vision of creating a clean, intuitive and tech-first product. It is designed for young Indians who are the global trendsetters.
Speaking at the launch, Mr. Sudarshan Venu, Managing Director, TVS Motor Company said, “Our dedication to harness technology and innovation towards a greener and more sustainable future has brought to us this incredibly desirable machine. This launch marks a defining moment in TVS Motors’ journey of showcasing a made-in-India EV, the TVS X. It has been designed for the global citizens, who are trendsetters and visionaries with a passion for technology. It is set to inspire a shift towards premium yet sustainable and technologically advanced mobility solutions. It leads the way to become a global benchmark for a machine that is born electric. The TVS X embodies innovation with a disruptive mindset. It has sustainability at its core and embodies the next era of clean mobility. With its remarkable performance, premium aesthetics, and integrated, intuitive, and personalised experiences, we believe it will redefine mobility worldwide.”
Booking for TVS X are open now on our website https://www.tvsmotor.com/electric-vehicle/tvs-x. Deliveries across 15 cities will start from Nov 2023 in a phase-wise manner.
TVS X will be available at a Thrill-electric introductory price of INR. 2,49,990/- (Ex-showroom Bengaluru) with portable 950W chargers at INR. 16,275 (including GST) and a 3kW Smart X Home rapid charger is also available as an option. FAME incentive is not applicable for TVS X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230824401679/en/
Contact information
For more information, please contact:
KS Harini – ks.harini@tvsmotor.com
Nikita Verma – nikita.verma@tvsmotor.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
